Literature DB >> 8644866

Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.

D M Mann1, T Iwatsubo, Y Ihara, N J Cairns, P L Lantos, N Bogdanovic, L Lannfelt, B Winblad, M L Maat-Schieman, M N Rossor.   

Abstract

Amyloid (A beta) deposition was investigated in cases of Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis, Dutch type, due to mutations in the amyloid precursor protein (APP) gene using the end-specific monoclonal antibodies BA27 and BC05 that recognize A beta 40 or A beta 42(43), respectively. In cases of APP717 mutation the predominant A beta species within plaques terminate at A beta 42(43) with relatively little A beta 40 being present. The total amount of A beta deposited as A beta 42(43) is significantly greater than in sporadic Alzheimer's disease, consistent with the suggestion that this mutation might influence the processing of APP so as to produce more of the highly aggregatable form, A beta 1-42. In cases of APP670/671 mutation the major peptide in plaques is also A beta 42(43), although the proportion of plaques containing A beta 40, and the total A beta load is similar to that in sporadic Alzheimer's disease. As in sporadic Alzheimer's disease, the vascular amyloid in APP670/671 and APP717 and in cases of hereditary cerebral hemorrhage with amyloidosis, Dutch type is predominantly A beta 40 in this latter disorder, however, parenchymal deposits are exclusively A beta 42(43). Although the various APP mutations may influence the type, quantity, and location of A beta deposited, the predominant, and possibly the initial, species deposited in the brain parenchyma is A beta 42(43).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644866      PMCID: PMC1861527     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

Review 1.  Normal and abnormal biology of the beta-amyloid precursor protein.

Authors:  D J Selkoe
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

2.  Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

Authors:  M Tabaton; M G Nunzi; R Xue; M Usiak; L Autilio-Gambetti; P Gambetti
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

3.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

Authors:  N Suzuki; T T Cheung; X D Cai; A Odaka; L Otvos; C Eckman; T E Golde; S G Younkin
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

4.  Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Authors:  G M Murphy; L S Forno; L Higgins; J M Scardina; L F Eng; B Cordell
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

5.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease.

Authors:  E Gowing; A E Roher; A S Woods; R J Cotter; M Chaney; S P Little; M J Ball
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

6.  Screening of the mis-sense mutation producing the 717Val-->Ile substitution in the amyloid precursor protein in Japanese familial and sporadic Alzheimer's disease.

Authors:  T Yoshizawa; Y Komatsuzaki; H Iwamoto; H Mizusawa; I Kanazawa
Journal:  J Neurol Sci       Date:  1993-07       Impact factor: 3.181

7.  Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation.

Authors:  K M Felsenstein; L W Hunihan; S B Roberts
Journal:  Nat Genet       Date:  1994-03       Impact factor: 38.330

8.  Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques.

Authors:  D M Mann; T Iwatsubo; H Fukumoto; Y Ihara; A Odaka; N Suzuki
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene.

Authors:  M Mullan; S Tsuji; T Miki; T Katsuya; S Naruse; K Kaneko; T Shimizu; T Kojima; I Nakano; T Ogihara
Journal:  Neurobiol Aging       Date:  1993 Sep-Oct       Impact factor: 4.673

10.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

View more
  38 in total

1.  Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.

Authors:  D M Mann; S M Pickering-Brown; A Takeuchi; T Iwatsubo
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Aβ plaques in Alzheimer's disease.

Authors:  Kai Liu; Tai L Guo; Jeremy Chojnacki; Hyoung-Gon Lee; Xinglong Wang; Sandra L Siedlak; Wei Rao; Xiongwei Zhu; Shijun Zhang
Journal:  ACS Chem Neurosci       Date:  2011-12-11       Impact factor: 4.418

Review 3.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

Review 4.  Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

Authors:  M Isabel G Lopez Sanchez; Peter van Wijngaarden; Ian A Trounce
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

5.  The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease.

Authors:  E Kövari; F R Herrmann; P R Hof; C Bouras
Journal:  Neuropathol Appl Neurobiol       Date:  2013-08       Impact factor: 8.090

6.  Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults.

Authors:  Y Hashimoto; T Niikura; Y Ito; H Sudo; M Hata; E Arakawa; Y Abe; Y Kita; I Nishimoto
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 7.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

8.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition.

Authors:  Byung Hee Han; Meng-Liang Zhou; Fadi Abousaleh; Robert P Brendza; Hans H Dietrich; Jessica Koenigsknecht-Talboo; John R Cirrito; Eric Milner; David M Holtzman; Gregory J Zipfel
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

10.  Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.

Authors:  Gregory S Day; Erik S Musiek; Catherine M Roe; Joanne Norton; Alison M Goate; Carlos Cruchaga; Nigel J Cairns; John C Morris
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.